Status:
UNKNOWN
Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type
Lead Sponsor:
Medical University of Vienna
Conditions:
MALT Lymphoma
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
The activity of monotherapy with Lenalidomide will be evaluated in patients with lymphoma of the mucosa associated lymphoid tissue (MALT).
Detailed Description
The primary objective of the study is to evaluate the clinical potential of Lenalidomide to induce objective/histologic responses in patients with MALT lymphoma. The secondary objectives are to evalu...
Eligibility Criteria
Inclusion
- Patients with histologically confirmed MALT lymphoma with measurable disease (stage I - IV)
- With first or greater relapse after HP-eradication, radiation or chemotherapy in case of gastric lymphoma
- Age \> 18 years
- Must be able to tolerate therapy, and have adequate cardiac, renal, and hepatic function, ECOG status of 0 - 2
- Must be capable of understanding the purpose of the study and have given written informed consent
Exclusion
- Lymphoma histology other than MALT lymphoma or MALT lymphoma with a diffuse large cell lymphoma ("high grade lymphoma") - component
- Use of any investigational agent within 28 days prior to initiation of treatment with lenalidomide
- History of malignancy other than squamous cell carcinoma, basal cell carcinoma of the skin or carcinoma in situ of the cervix within the last 5 years
- Major surgery, other than diagnostic surgery, within the last 4 weeks
- Evidence of CNS involvement
- A history of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant and adversely affecting compliance to study drugs
- Severe peripheral polyneuropathy
- Clinically significant cardiac disease (e.g., congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias not well controlled with medication) or myocardial infarction within the last 6 months
- Inadequate hematological status at baseline prior to study entry: Dependency on red blood cell and/or platelet transfusions, ANC (absolute neutrophil count (segmented + bands)) \< 1.0 x 109/L
- Patients with active opportunistic infections
- Pregnancy
- Uncontrolled diabetes mellitus
- Preexisting thromboembolic events at start of study
Key Trial Info
Start Date :
July 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2011
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00923663
Start Date
July 1 2009
End Date
June 1 2011
Last Update
September 28 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dept of Internal Medicine
Vienna, Austria, A-1090